title: Functional evidence for an angiotensin IV receptor in rat resistance arteries.
abstract: To distinguish between the different effects of angiotensin IV (Ang IV) on resistance artery vasoreactivity, freshly isolated rat mesenteric arteries were perfused and the changes in their diameter were recorded under various conditions. Ang IV exerted vasoconstrictor effects on both normal vessels and vessels that had been precontracted with phenylephrine or serotonin. This effect was abolished by losartan or candesartan cilexetil, two type 1 angiotensin receptor antagonists, but not by PD 123319, a type 2 angiotensin receptor antagonist. No tachyphylaxis was observed for the vasoconstrictor effect of Ang IV. N(G)-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, had no effect on Ang IV-induced vasoconstriction, whereas indomethacin, a cyclooxygenase inhibitor that was inactive by itself, influenced Ang IV-induced vasoconstriction, suggesting that Ang IV could stimulate the release of prostaglandins. Treatment of preconstricted vessels by candesartan cilexetil unraveled a vasodilator effect of Ang IV that was abolished by PD 123319, a type 2 angiotensin receptor antagonist. Unexpectedly, Ang IV still produced a vasoconstrictor effect on normal or preconstricted vessels after blockade of both type 1 and type 2 angiotensin receptors. Taken together, these results show that Ang IV influences resistance artery vasoreactivity via different mechanisms, one of which implicates a functionally active type 4 angiotensin receptor.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale U 141 and Institut Fédératif de Recherche Circulation-Lariboisière, Université Paris VII, Hôpital Lariboisière, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Loufrani
authors.forename: D
authors.initials: D
authors.lastname: Henrion
authors.forename: D
authors.initials: D
authors.lastname: Chansel
authors.forename: R
authors.initials: R
authors.lastname: Ardaillou
authors.forename: B I
authors.initials: BI
authors.lastname: Levy
mesh_terms: D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000494:pharmacology; D004347:Drug Interactions; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D019808:Losartan / Q000494:pharmacology; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D010477:Perfusion; D010656:Phenylephrine / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011945:Receptors, Angiotensin / Q000145:classification / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology; D013618:Tachyphylaxis / Q000502:physiology; D013777:Tetrazoles; D014655:Vascular Resistance / Q000502:physiology*
chemical_list: D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007093:Imidazoles; D011725:Pyridines; D011945:Receptors, Angiotensin; D013777:Tetrazoles; C073402:PD 123319; D010656:Phenylephrine; D012701:Serotonin; D019808:Losartan; C077793:candesartan cilexetil; D019331:NG-Nitroarginine Methyl Ester; D007213:Indomethacin